Brodalumab

Specification

• Cat#: THA-0076
• Product Name: Brodalumab
• Description: Brodalumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.
• Sequences: Not Available
• Molecular Weight: Not Available
• Introduction: Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Appearance: Not Available
• Endotoxin Level: < 0.001 EU/μg of the protein by the LAL method

Pharmaceutical Information

• Pharmacodynamics: Increase in the level of IL-17 due to blocking of its receptors.